Pfizer (PFE)
25.31
-0.37 (-1.45%)
NYSE · Last Trade: Oct 9th, 2:35 PM EDT
A significant surge in capital flowing into short-bias Exchange-Traded Funds (ETFs) has sent a clear signal through the financial markets: investor sentiment is shifting towards caution and a potential stock market pullback. This notable trend, particularly pronounced in recent weeks, suggests that a growing number of investors are actively positioning
Via MarketMinute · October 9, 2025
The small-cap pharmaceutical company may be the next in line as takeover fever heats up.
Via The Motley Fool · October 9, 2025
The relentless ascent of the U.S. stock market has hit a significant speed bump, as both the S&P 500 and Nasdaq Composite have retreated from their recent record highs. This pullback, occurring after weeks of robust gains, signals a period of reassessment for investors grappling with a confluence
Via MarketMinute · October 9, 2025
Looking for the most active stocks in the S&P500 index on Thursday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.
Via Chartmill · October 9, 2025
Via The Motley Fool · October 9, 2025
Via The Motley Fool · October 9, 2025
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via MarketBeat · October 9, 2025
Roche has a promising GLP-1 drug that is entering phase 3 trials.
Via The Motley Fool · October 9, 2025
Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Wednesday. Discover the stocks that are generating the highest trading volume and driving market activity.
Via Chartmill · October 8, 2025
Shares of scientific instruments company Waters Corporation (NYSE:WAT)
jumped 3.2% in the morning session after Rothschild & Co initiated coverage on the stock with a 'Buy' rating and a $390 price target.
Via StockStory · October 8, 2025
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of
Via MarketMinute · October 8, 2025
Washington D.C., October 8, 2025 – The U.S. federal government remains in the throes of a shutdown, now entering its second week, as lawmakers in Washington continue to grapple with a stalemate over federal funding for Fiscal Year 2026. This ongoing budgetary impasse, which commenced on October 1, 2025,
Via MarketMinute · October 8, 2025
These biotechs could finally come into their own by the end of the decade.
Via The Motley Fool · October 8, 2025
Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential
Via MarketBeat · October 8, 2025
Investors reacted to the company’s leadership shake-up and new data from its ulcerative colitis therapy Omvoh showing sustained remission over four years.
Via Stocktwits · October 7, 2025
Explore the S&P500 index on Tuesday and find out which stocks are the most active in today's session. Stay updated with the stocks that are capturing market interest.
Via Chartmill · October 7, 2025
Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL)
fell 4.4% in the morning session after Citigroup analyst Patrick Donnelly downgraded the stock to 'Neutral' from 'Buy' and lowered the price target. The firm cut its price projection for QuidelOrtho to $33 from $40, a reduction of 17.5%. This adjustment by Citigroup reflected a change in the firm's outlook on the company's stock performance. The downgrade and price target cut highlighted concerns about QuidelOrtho's near-term growth prospects.
Via StockStory · October 7, 2025
Washington has shut down -- but don't fall into a panic, because these things don't last.
Via The Motley Fool · October 7, 2025
Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.
Via The Motley Fool · October 7, 2025
The deal on drug prices between the US Administration and Pfizer will leave the margins of innovative pharma companies intact.
Via Talk Markets · October 7, 2025
Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.
Via MarketBeat · October 7, 2025
Tariffs aren't likely to weigh on growth at these companies.
Via The Motley Fool · October 7, 2025
Eli Lilly just got great news, courtesy of Pfizer and Trump, leading shares to their highest level in five months. Its rally may just be getting started.
Via MarketBeat · October 6, 2025
Washington D.C., October 6, 2025 – The American labor market appears to have hit a significant speed bump, with Moody's Analytics reporting "essentially no job growth" for the U.S. in September 2025. This concerning assessment comes at a critical juncture for the economy, compounded by an ongoing federal government
Via MarketMinute · October 6, 2025